EELS-TALC

**EELS-TALC** is a preclinical, autologous chondrocyte-based tissue-engineering therapy for repair of cartilage injuries, particularly knee cartilage defects. The approach expands patient-derived chondrocytes in a three-dimensional thermoresponsive polymer scaffold, reported by GN Corporation as FestiGel, before implantation at the damaged cartilage site. The culture method is intended to preserve a hyaline-cartilage phenotype and enhance retention of hyaluronic acid, while reported preclinical studies describe increased miRNA-140 expression, lower senescence-associated markers, and enrichment of chondroprogenitor and mesenchymal-stem-cell-like populations without genomic modification. ([gncorporation.com](https://gncorporation.com/en/consulting-research-patents-en/cell-therapy-solutions-en/))

Other names

EELS + TALCEnriched with Essentials and Lapped in Scaffold Transplant-suitable Autologous Leveraged Chondrocytes